Cardiovascular Effects of Home Dialysis Therapies: A Scientific Statement From the American Heart Association

Authors:
  • MSMark J. Sarnak
    Mark J. Sarnak
  • BABourne L. Auguste
    Bourne L. Auguste
  • EBEdwina Brown
    Edwina Brown
  • ACAlexander R. Chang
    Alexander R. Chang
  • GCGlenn M. Chertow
    Glenn M. Chertow
  • MHMary Hannan
    Mary Hannan
  • CHCharles A. Herzog
    Charles A. Herzog
  • ANAnnie-Claire Nadeau-Fredette
    Annie-Claire Nadeau-Fredette
  • WTWai Hong Wilson Tang
    Wai Hong Wilson Tang
  • AWAngela Yee-Moon Wang
    Angela Yee-Moon Wang
  • DWDaniel E. Weiner
    Daniel E. Weiner
  • CCChristopher T. Chan
    Christopher T. Chan

Abstract
Cardiovascular disease is the leading cause of morbidity and mortality in patients with end-stage kidney disease. Currently, thrice-weekly in-center hemodialysis for 3 to 5 hours per session is the most common therapy worldwide for patients with treated kidney failure. Outcomes with thrice-weekly in-center hemodialysis are poor. Emerging evidence supports the overarching hypothesis that a more physiological approach to administering dialysis therapy, including in the home through home hemodialysis or peritoneal dialysis, may lead to improvement in several cardiovascular risk factors and cardiovascular outcomes compared with thrice-weekly in-center hemodialysis. The Advancing American Kidney Health Initiative, which has a goal of increasing the use of home dialysis, is aligned with the American Heart Association’s 2024 mission to champion a full and healthy life and health equity. We conclude that incorporation of interdisciplinary care models to increase the use of home dialysis therapies in an equitable manner will contribute to the ultimate goal of improving outcomes for patients with kidney failure and cardiovascular disease.

This publication has 155 references indexed in Scilit: